# A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer

> **NCT06838546** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tasly Biopharmaceuticals Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** B1962

## Key facts

- **NCT ID:** NCT06838546
- **Lead sponsor:** Tasly Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-24
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-01-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06838546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06838546, "A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06838546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*